We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+16.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.25B
AUM Growth
+$394M
Cap. Flow
+$407M
Cap. Flow %
18.04%
Top 10 Hldgs %
64.72%
Holding
86
New
21
Increased
10
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$148M
2
ANAB icon
AnaptysBio
ANAB
+$99.1M
3
KURA icon
Kura Oncology
KURA
+$60.7M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
5
DSGN icon
Design Therapeutics
DSGN
+$38.4M

Top Sells

Rank Stock Value
1
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$44.3M
2
GERN icon
Geron
GERN
+$30.1M
3
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$10M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$9.77M
5
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$7.51M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$169M
$12.1M 0.54%
+602,600
New +$10.8M
ELDN icon
27
Eledon Pharmaceuticals
ELDN
$262M
$11.9M 0.53%
+1,115,721
New +$16.8M
KRON
28
DELISTED
Kronos Bio
KRON
$11.3M 0.5%
387,357
– –
AMTI
29
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$10.5M 0.47%
239,443
-910,557
-79% -$44.3M
KLRS
30
Kalaris Therapeutics
KLRS
$79.5M
$10.5M 0.46%
19,435
– –
NUVB.WS
31
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$10.1M 0.45%
+963,333
New +$2.79M
TBIO
32
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$9.84M 0.44%
+596,900
New +$13.6M
TNGX icon
33
Tango Therapeutics
TNGX
$4.34B
$8.9M 0.39%
800,000
– –
ITOS
34
DELISTED
iTeos Therapeutics
ITOS
$8.89M 0.39%
260,000
– –
ALPN
35
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.86M 0.35%
741,290
– –
SYRS
36
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.48M 0.33%
100,000
– –
CCCC icon
37
C4 Therapeutics
CCCC
$393M
$7.4M 0.33%
200,000
– –
DNTH icon
38
Dianthus Therapeutics
DNTH
$5.55B
$6.59M 0.29%
+34,772
New +$5.85M
PRTA icon
39
CALL
Prothena Corp
PRTA
$448M
$6.28M 0.28%
+250,000
New +$4.7M
LOGC
40
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$5.01M 0.22%
688,700
-86,300
-11% -$710K
BOLT icon
41
Bolt Biotherapeutics
BOLT
$7.72M
$4.94M 0.22%
+7,500
New +$4.88M
JYAC
42
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.92M 0.22%
500,000
– –
CYCN icon
43
Cyclerion Therapeutics
CYCN
$15.2M
$4.48M 0.2%
80,314
– –
OBIO icon
44
Orchestra BioMed
OBIO
$231M
$4.48M 0.2%
400,000
– –
NGM
45
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.17M 0.19%
143,567
– –
KYMR icon
46
Kymera Therapeutics
KYMR
$8.73B
$3.89M 0.17%
100,000
– –
DYN icon
47
Dyne Therapeutics
DYN
$4.28B
$3.34M 0.15%
215,000
– –
VINCW
48
DELISTED
Vincerx Pharma, Inc. Warrant
VINCW
$2.9M 0.13%
150,000
– –
WHWK
49
Whitehawk Therapeutics
WHWK
$182M
$2.67M 0.12%
+138,185
New +$3.18M
BCAB icon
50
BioAtla
BCAB
$5.86M
$2.54M 0.11%
1,000
– –
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2021 Portfolio in Review

As of Q1 2021, EcoR1 Capital held 86 positions worth $2.25B, up 21% from $1.86B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $407M of net new capital in Q1 2021, opening 21 new positions and adding to 10 existing holdings. Its largest new stake was Nuvation Bio: 13,247,017 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Applied Molecular Transport Inc. Common Stock, an estimated $44.3M trimmed.

  • EcoR1 Capital's largest Q1 2021 buy was Nuvation Bio: 13,247,017 shares worth $138M.
  • EcoR1 Capital added most to AnaptysBio in Q1 2021, an estimated $99.1M increase.
  • EcoR1 Capital's biggest Q1 2021 reduction was Applied Molecular Transport Inc. Common Stock, cutting an estimated $44.3M.
  • EcoR1 Capital fully exited Geron in Q1 2021, selling an estimated $30.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $2.25B portfolio in Q1 2021.
  • EcoR1 Capital opened 21 new positions and closed 15 in Q1 2021.
  • EcoR1 Capital's portfolio value rose 21% quarter-over-quarter to $2.25B.

Based on EcoR1 Capital's 13F filing for Q1 2021, filed 17 May 2021.